ATLANTA, Jan. 22, 2009 (GLOBE NEWSWIRE) -- OTC Stock Review announces that it has initiated coverage of Gamma Pharmaceuticals, Inc. (OTCBB:GMPM). Gamma Pharmaceuticals, headquartered in Las Vegas, NV, is a fast growing marketing and product formulation company focused on the global health and nutriceuticals market in North America and China. Led by an experienced management team with 45 years experience in product formulation and marketing, Gamma Pharmaceuticals' management and directors have been responsible for products that generate revenue of more than $1.0 billion annually. In our opinion, Gamma Pharmaceuticals shares could see an explosive move as its management team "does it again" and sales of products utilizing its proprietary "Gel Delivery Technology" take off in both the U.S. and China.
According to a report on the company's website, Gamma Pharmaceuticals management believes the Company could, potentially, generate revenue of $31 million and net income of $1.5 million for 2009, revenue of $91 million with $17 million in net income for 2010, and revenue over $160 million with more than $55 million in net income.
In our opinion, the stock has been oversold during the recent crisis in the financial markets, making it, what we believe to be, a tremendous opportunity for investors.
The complete report is available at http://www.otcstockreview.com/files/GMPM/GMPM_Review.pdf.
Additionally, more information on Gamma Pharmaceuticals, Inc. is available at http:// www.gammapharma.com.
NOTE: The purpose of this release is to introduce the reader to OTCStockReview.com and Gamma Pharmaceuticals, Inc. OTC Stock Review is not a Registered Investment Advisor or a Broker/Dealer. Information and opinions presented in this release are solely for informative purposes and not intended as investment advice. This document contains information obtained from public sources about Gamma Pharmaceuticals, Inc., but does not contain all the relevant material information necessary to evaluate the company. This release is not to be considered an offer to buy, sell, hold, and/or otherwise trade in the securities of Gamma Pharmaceuticals, Inc., as profiled. OTC Stock Review has been compensated sixty nine thousand shares of Gamma Pharmaceuticals Inc. common stock and three thousand five hundred dollars to perform investor relations services for Gamma Pharmaceuticals, Inc. and officers, directors, and employees of OTC Stock Review, may hold a long or short equity position of a profiled company and may trade in these securities for their own accounts. Carefully review profiled companies with your investment advisor, stockbroker, or other such professional. OTC Stock Review is not liable for any investment decisions by its readers or their advisors. Readers are encouraged to obtain copies of the profiled Company's periodic reports filed with United States Securities and Exchange Commission, which are generally available at http://www.sec.gov. You can view our complete disclaimer at http://www.otcstockreview.com/disclaimer.htm